Bank of America Corp. (BAC) Pops 2.8% for February 22

Equities Staff |

One of the S&P 500’s big winners for Monday February 22 was Bank of America Corp. (BAC) as the company’s stock climbed 2.8% to $12.47 on volume of 64.09 million shares.

The stock opened at $12.38 and saw an intraday low of $12.36 and an intraday high of $12.50. All told, the day saw a per-share gain of $0.3392. The stock’s average daily volume of 110.23 million and 10.38 billion shares outstanding. Bank of America Corp. now has a 50-day SMA is $14.86 and 200-day SMA is $16.30, and it has a 52-week high of $18.48 and a 52-week low of $10.99.

Bank of America Corporation is a bank holding and a financial holding company. Through its subsidiaries, it provides banking and non-banking financial services and products throughout the United States and in selected international markets.

Based out of Charlotte, NC, Bank of America Corp. has 215,200 employees and, after today’s trading, reached a market cap of $129.43 billion. The stock’s P/E Ratio is 8.9. Its P/S ratio is 1.34, P/B ratio is 0.55, and P/FCF ratio is 6.7.

For a complete fundamental analysis analysis of Bank of America Corp., check out Equities.com’s Stock Valuation Analysis report for BAC. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.

The S&P 500 represents the industry standard for large-cap indices. While the Dow Jones Industrial Average (DJIA) may be the most visible stock market index in the country, the S&P 500 has long been relied on by industry insiders and fund managers as the more reliable gauge of portfolio performance.

While the DJIA is price-weighted and only includes 30 stocks, the S&P 500 uses a weighting system that factors in market cap and the size of a company’s free float while including some 500 stocks for a more comprehensive look at the broader markets’ performance. Its performance is far more representative of the large- and mega-cap stocks for any period of time.

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Comments

Emerging Growth

Immunovaccine Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.

Private Markets

Trustify

Trustify provides trust and safety in both the digital and physical worlds through our vast network of on-demand Private Investigators.By removing the large retainers and high hourly rates that traditional…

Lyft

Lyft matches drivers using their own personal vehicles with passengers who request rides through the smartphone app, and the passengers pay automatically through the app. When using Lyft, passengers have…